Stock Ratings / Health Care / DNA / insiders

SANA (46) GLUE (33) MGTX (27) PRME (21) ⌘ Pro Terminal →

Ginkgo Bioworks Holdings Inc. (Class A) (DNA) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$12.74 -4.35% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot)

Ginkgo Bioworks Holdings Inc. (Class A) (DNA) carries a Roarable Rating of E (Strong Sell) with 28/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $819.7M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk E

Each axis scored 0–20

12M PRICE TARGET CONE-13.5% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for DNA)Realized 20D OHLCV Swing Band: ±12.5%

SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

DNA Smart-Money Thermometer: NET EXECUTIVE TRIMMING / PROFIT-TAKING

Explore All 13F & Congress Whales →

▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (DNA)

No recent open-market Form 4 cluster sales or emergency dumps flagged on DNA. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring DNA)

✓Walkthrough of DNA's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

DNA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +50.59%📐 HORIZONTAL RANGE

2026-10-30O $12.12H $12.74L $10.60C $12.74VOL 2.73M

RES: $19.53SUP: $5.94SMA50: $9.55SMA200: $8.59

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

DNA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 DNA Butterfly Map → + Track DNA →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. -25.1% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on DNA today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for DNA. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for DNA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (DNA)

Health Care Rank #964 of 1016 ⚔️ SANA vs DNA Full Matrix →

1. Head-to-Head Health Care Peer Comparison (DNA vs. SANA, GLUE, MGTX, PRME)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Ginkgo Bioworks Holdings Inc. (Class A) (DNA) ranks #964 by composite RQD confidence (28/100, grade E) and #383 by equity capitalization ($819.7M). Within this direct 5-issuer industry benchmark cohort, DNA leads on earnings valuation at N/A trailing P/E, while DNA leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. SANA currently holds the highest overall quantitative score in the immediate peer group at 46/100 (D) compared with DNA at 28/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
DNA ACTIVE Ginkgo Bioworks Holdings Inc. (Class A)	E	28/100	—	—	-35.0%	-4.35%	$819.7M	Benchmark Subject
SANA Sana Biotechnology Inc.	D	46/100	—	—	-35.0%	+3.42%	$814.3M	/sana-vs-dna →
GLUE Monte Rosa Therapeutics Inc.	E	33/100	—	—	-35.0%	+0.18%	$927.4M	/glue-vs-dna →
MGTX MeiraGTx Holdings plc	E	27/100	—	—	-35.0%	-0.46%	$932.1M	/mgtx-vs-dna →
PRME Prime Medicine Inc.	E	21/100	—	—	-35.0%	-2.24%	$950.4M	/prme-vs-dna →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001830214

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Ginkgo Bioworks Holdings Inc. (Class A) (DNA) reported GAAP revenue of $170.2M (-25.1% vs. FY2024 revenue of $227.0M , and -32.3% cumulative change since FY2023) , GAAP net income of -$313.0K, operating cash flow of -$171.1M, and free cash flow of -$178.7M (+53.2% YoY). On the balance sheet, DNA closed FY2025 with $1.12B in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$170.2M	-$313.0K	-$171.1M	-$178.7M	$1.12B	—
FY2024 (FY)	2024-12-31	$227.0M	-$547.0K	-$319.6M	-$382.1M	$1.38B	—
FY2023 (FY)	2023-12-31	$251.5M	-$893.0K	-$295.5M	-$295.5M	—	—

3. DNA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is DNA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Ginkgo Bioworks Holdings Inc. (Class A) (NYSE: DNA) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 28/100 at a spot price of $12.74 (-4.35% 1D, market cap $819.7M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 7/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, DNA ranks #964 in composite RQD confidence.

How does DNA compare to SANA and GLUE in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), DNA carries a Roarable E (28/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, SANA (Sana Biotechnology Inc.) holds a D grade (46/100 RQD, P/E N/A, ROIC -35.0%, cap $814.3M) and GLUE (Monte Rosa Therapeutics Inc.) posts a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $927.4M). Among the 5-stock peer group, DNA leads on earnings multiple (N/A) while DNA leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for DNA?

Per DNA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001830214), Ginkgo Bioworks Holdings Inc. (Class A) generated $170.2M in revenue (-25.1% YoY), -$313.0K in net income, and -$178.7M in free cash flow against $1.12B in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is DNA trading relative to its 50-day, 200-day, and 52-week technical levels?

DNA last traded at $12.74 (-4.35% on volume of 2,897,891 shares), positioning the stock +33.40% above its 50-day simple moving average ($9.55) and +48.31% above its 200-day simple moving average ($8.59). Across its 52-week range of $5.37 to $18.22, DNA sits at the 57.4% percentile with a 14-day RSI of 52.0 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($11.15 to $14.33).

DNA Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Are DNA insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies DNA leadership and institutional positioning as: NET EXECUTIVE TRIMMING / PROFIT-TAKING.

Direct Sub-Reports: DNA RQD Cockpit DNA 12M Forecast DNA Earnings & Move DNA Dividends & DRIP DNA Insiders & 13F DNA Whale Options DNA Profit Sankey DNA News & Why